Performance of multigene panel testing in hereditary prostate cancer
Hereditary prostate cancer (HPC) is defined as ≥3 first degree relatives with prostate cancer (PC); 2 relatives diagnosed ≤ age 55; or PC in ≥3 generations. Genes associated with HPC pose a risk for younger age of diagnosis and more lethal prostate cancer, and for developing other primary cancers.
Multi-gene testing using any panel identified pathogenic or likely pathogenic variants in 18% (17/94) of men who met HPC criteria.
Multi-gene testing using a panel targeted for prostate cancer genes performed equally well in men who met strict HPC criteria (21.4% (3/14) positive rate) and in men who did not meet HPC criteria but were clinically selected for genetic testing and had at least one relative with prostate cancer (23.1% (6/26) positive rate).
This data supports an MGPT approach in cases where hereditary PC predisposition is suspected but strict HPC criteria are not met.
Authors: Mary Pritlzaff; Kyle Allen; Holly LaDuca; Richard J. Fantus; Brian T. Helfand